A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to TNF-α antagonist therapy Estudio Fase III, doble ciego, aleatorizado, controlado con placebo, de grupos paralelos, multicéntrico, para investigar la eficacia clínica de ofatumumab en pacientes adultos con artritis reumatoide activa y respuesta inadecuada a la terapia con antagonistas TNFα To demonstrate efficacy of ofatumumab in reducing clinical signs and symptoms in adult RA patients after a single course of ofatumumab Demostrar la eficacia de ofatumumab para reducir los signos y sín...

• Country None
• organs None
• Specialty None

A multicentre open-label, dose-escalation, trial of zanolimumab in combination with CHOP chemotherapy in subjects with CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement To investigate safety and tolerability of ascending doses of zanolimumab up to 20mg/kg in combination with CHOP chemotherapy in order to define a maximum tolerated dose (MTD) in subjects with CD4 posi...

• Country None
• organs None
• Specialty None

A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy and safety in adult patients with active rheumatoid arthritis receiving non-biologic background disease-modifying antirheumatic drugs To demonstrate the efficacy of ofatumumab in reducing clinical signs and symptoms in adult RA patients after a single course of ofatumumab

• Country None
• organs None
• Specialty None

An open label clinical pilot study with local injection of human antibody (HuMax-Inflam) for the treatment of inflammatory psoriasis The purpose of the study is to investigate whether treatment with HuMax-Inflam induces regression or reduces progression of inflammatory, progressive psoriasis in comparison with isotonic saline solut...

• Country None
• organs None
• Specialty None

An Open label single arm trial investigating zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have Failed Standard Platinum-based Chemotherapy To investigate zalutumumab in combination with BSC in terms of overall survival in non-curable patients with recurrent and/or metastatic disease who have failed after at least one course of standard-b...

• Country None
• organs None
• Specialty None

A double-blind, randomized, placebo-controlled, multi-center, Clinical Trial of ofatumumab, a fully human monoclonal anti-CD20 antibody in patients with moderate to severe stage Chronic Obstructive Pulmonary Disease To evaluate efficacy of ofatumumab in decreasing inflammation in COPD assessed by bronchial biopsies.

• Country None
• organs None
• Specialty None

Dose-escalating and cohort expansion safety trial of tissue factor specific antibody drug conjugate tisotumab vedotin (HuMax®-TF-ADC) in patients with locally advanced and/or metastatic solid tumors known to express tissue factor • To establish the tolerability of HuMax-TF-ADC dosed three times q4wk in a mixed population of patients with specified solid tumors

• Country None
• organs None
• Specialty None

An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with refractory or relapsed Non-Cutaneous CD4+ T-Cell Lymphoma The primary objective of this trial is to explore the efficacy of HuMax-CD4 treatment with respect to tumor response and duration in patients with refractory or relapsed non-cutaneous CD4+ T-cell lymp...

• Country None
• organs None
• Specialty None

A double-blind, randomized, placebo controlled, dose escalation, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthritis who have previously failed one or more disease modifying anti-rheumatic drugs Part A: To evaluate the safety of HuMax-CD20 in patients with active rheumatoid arthritis. Part B: To evaluate the efficacy of HuMax-CD20 in patients with active rheumatoid arthritis using the America...

• Country None
• organs None
• Specialty None

A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in Combination with Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer Patients To demonstrate that treatment with zalutumumab in combination with chemo-radiation is superior to chemo-radiation alone in terms of progression free survival in treatment naïve stage IIIA–IIIB NSCLC p...

• Country None
• organs None
• Specialty None